Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Equity Premium Income ETF (JEPI) vs Medtronic PLC (MDT) Price & Performance

JPMorgan Equity Premium Income ETFTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Medtronic PLC — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.87, while Medtronic PLC trades at $90.9 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals.

JEPIMDT
Sector
Income / Options OverlayHealth
52-Week High
$59.88$105.35
52-Week Low
$55.29$73.75
Market Cap
$116.07B
Enterprise Value
$134.82B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Equity Premium Income ETF

JEPI trades at $57.86, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on generating income through covered calls, offering monthly dividends, though recent news highlights underperformance versus peers and tax inefficiencies. Key support and resistance cluster around $58.

Outlook is mixed: JEPI provides steady income attractive to retirees, but faces competition from higher-yielding alternatives and potential opportunity cost from capped upside. Risks include yield compression, tax treatment of distributions, and active management underperformance. Investors should weigh income needs against total return potential.

Medtronic PLC

Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.

The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

Read more on JEPI

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT